2 Information about pemigatinib

Marketing authorisation indication

2.1 Pemigatinib (Pemaryze, Incyte Corporation) has a conditional marketing authorisation for 'the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price of pemigatinib 13.5 mg tablets is £7,159.04 for a pack of 14 (company submission), which is an annual cost of £124,430. The company has a commercial arrangement. This makes pemigatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)